Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19 -- The high-throughput, highly sensitive cobas SARS-CoV-2 Test under FDA Emergency Use Authorisation can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19 -- Accurate, reliable and early detection of SARS-CoV-2 in potentially exposed individuals can help limit the spread of disease PLEASANTON, Calif., May 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Test for use on the widely available, high-throughput cobas 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19. This authorisation supports the guidance update from the U.S. Centers for Disease Control and Prevention (CDC) to expand SARS-CoV-2 testing to include people without symptoms